Glenmark Pharmaceuticals Poland Signs 5-Year Contract For Eluzzion CRM
Data3s today announced that Glenmark Pharmaceuticals Sp. z o.o., the Polish division of Glenmark Pharmaceuticals Ltd. (GPL), has signed a 5-year agreement with Data3s for eluzzion CRM, a leading platform for customer relationship management and sales force support
Online PR News – 04-January-2011 – – Data3s today announced that Glenmark Pharmaceuticals Sp. z o.o., the Polish division of Glenmark Pharmaceuticals Ltd. (GPL), has signed a 5-year agreement with Data3s for eluzzion CRM, a leading customer relationship management and sales force support platform.
An additional contract for the same period was signed with pureIT, Data3s’ service partner in Poland, covering a range of IT support services on behalf of Glenmark Poland.
Glenmark Pharmaceuticals Ltd. (GPL), a research-driven, global, integrated pharmaceutical company headquartered in Mumbai, India, is one of the leading providers of generic medicines in Central Europe. Data3s is a leading provider of CRM software solutions for the pharmaceutical industry, with a rapidly-growing roster of clients across Europe.
Asked why his company chose eluzzion CRM, Artur Mazurkiewicz, National Sales Manager at Glenmark Poland, responded that the decision was based partly on the positive experience of his colleagues in other CEE countries.
“The Data3s system fulfilled our prior expectations and it had the recommendation of our colleagues from Glenmark [Czech Republic and Slovakia],” said Mr. Mazurkiewicz.
The tender for CRM was overseen by Jindrich Strnad, IT Manager, Europe for Glenmark.
Describing the rationale behind their decision-making process, Mr. Mazurkiewicz added:
“The decision to search for a new ETMS system was connected with the increasing demand from our Sales Department for better possibilities for targeting, planning and monitoring visits and activities.
“Additionally, we were seeking a system which would support us in the management of other fields, includingmedical samples distribution and financial documents distribution, and which would contain an HR module and an e-learning platform.”
According to Mr. Mazurkiewicz, eluzzion CRM fulfilled all of Glenmark Poland’s requirements and more.
“For our Area Sales Managers, additional benefits of the system are the wide range reports covering the quantity and quality of visits and activities performed by Representatives,” said Mr. Mazurkiewicz, noting that “receiving such reports promptly has a direct effect on good team management.”
Unsurprisingly, Mr. Mazurkiewicz said that price was also an important factor. “We searched for a system which would be cost effective,” he said, adding, “I am sure that our cooperation with Data3s regarding the eluzzion CRM system will be beneficial for our Sales, Marketing and Financial Departments.”
Reacting to the news, Data3s’ CEO, Antonin Lukes, said, “After successfully serving Glenmark in the Czech Republic and Slovakia for more than two years, we are very glad to see our relationship with Glenmark growing in Europe. This development reflects not just the quality of our product, but the strength of our business.”
The decision to implement eluzzion CRM in Glenmark’s largest CEE subsidiary allows Glenmark countries to band together around a common platform with the advantage of generating accurate and consistent reports across the region.
Asked whether the expansion within Glenmark reflects Data3s’ growth strategy for the coming year, Data3s’ Sales Director, Cristian Burrows, replied that corporate relationship building is a cornerstone – not just a result – of good service.
“We believe we are the most effective when serving multiple countries or corporate affiliates together. It allows for greater standardization without losing sight of the unique demands of individual countries. When more countries are operating on the same platform, there tends to be greater interest from headquarters and more ways for top management to be involved and know what’s going on in the region.”
About Glenmark Pharmaceuticals Ltd.
Glenmark (GPL) is a research-driven, global, fully integrated pharmaceutical company headquartered at Mumbai, India. We employ over 4100 people across the globe, with branded generic formulation interests in over 95 countries across the world including India, Europe, Brazil, Latin America, Russia/CIS, Africa and Asia.
Copyright 2015 Online PR Media | PO Box 5043 | La Quinta, CA 92248